98%
921
2 minutes
20
Background: There are challenges in the diagnosis of TB in people with smear-negative pulmonary TB (SNPTB) in resource-limited settings. We evaluated the diagnostic usefulness of Xpert MTB/RIF compared with TB culture among SNPTB.
Methods: The study was a cross-sectional study among patients with SNPTB. The Xpert MTB/RIF tests and sputum culture (using Lowenstein-Jensen medium) were performed. Sensitivity and specificity were calculated.
Results: Of 150 patients studied, the sensitivity and specificity of GeneXpert MTB/RIF were 81.8 and 97.4%, respectively.
Conclusion: The sensitivity and specificity of Xpert MTB/RIF assay was comparative with culture in SNPTB patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/trstmh/traa019 | DOI Listing |
Front Med (Lausanne)
August 2025
Department of Pathology and Laboratory Diagnosis, College of Veterinary Medicine, Qassim University, Buraydah, Saudi Arabia.
Tuberculosis (TB) remains one of the leading causes of infectious disease mortality worldwide, increasingly complicated by the emergence of drug-resistant strains and limitations in existing diagnostic and therapeutic strategies. Despite decades of global efforts, the disease continues to impose a significant burden, particularly in low- and middle-income countries (LMICs) where health system weaknesses hinder progress. This comprehensive review explores recent advancements in TB diagnostics, antimicrobial resistance (AMR surveillance), treatment strategies, and vaccine development.
View Article and Find Full Text PDFContemp Clin Trials
September 2025
Weill Cornell Medicine Center for Global Health, New York, NY, USA.
Introduction: Preclinical and clinical study data show that combining bedaquiline (B or BDQ), moxifloxacin (M), and pyrazinamide (Z), known as BMZ, has potent antimicrobial activity that might shorten treatment duration for drug-susceptible pulmonary tuberculosis.
Methods/design: We describe the design of Tuberculosis Trials Consortium (TBTC) Study 38/CRUSH-TB (NCT05766267), an open-label multicenter international randomized controlled phase 2C trial that compares two four-month regimens, BMZ plus rifabutin (Rb) (2BMZRb/2BMRb) or BMZ plus delamanid (D or DLM) (2BMZD/2BMD), with standard 6-months isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE). All drugs are administered seven days per week, under direct observation, at least five days per week.
Int J Antimicrob Agents
September 2025
Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Laboratory Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan; Department of Laboratory Medicine, National Taiwan U
Objectives: To evaluate the diagnostic performance of Roche cobas MTB and MTB-RIF/INH assays for detecting Mycobacterium tuberculosis complex (MTBC) and resistance to isoniazid (INH) and rifampicin (RIF).
Methods: This multicenter study was conducted in Taiwan between September 2023 and June 2024. Clinical specimens were collected from adult patients with presumptive tuberculosis (TB).
Open Forum Infect Dis
September 2025
DSI/NRF Centre of Excellence for Biomedical TB Research, Faculty of Health Sciences, University of the Witwatersrand, National Health Laboratory Service, Johannesburg, South Africa.
Background: Tuberculosis (TB) diagnosis remains difficult in children under 5 years of age (under-5s), who have high TB morbidity and mortality rates. In a high-burden TB setting, we investigated the diagnostic characteristics of Xpert MTB/RIF Ultra testing of tongue swabs (TS-XU) collected from under-5s.
Methods: In a masked, prospective, observational study, tongue swabs were collected from enrolled hospitalized under-5s deemed high risk for TB disease who were categorized into 1 of the following: confirmed, unconfirmed, or unlikely TB.
BMC Musculoskelet Disord
September 2025
Departments of Orthopedics, Hangzhou Ninth People's Hospital, Hangzhou, Zhejiang, 310000, China.
Background: The burden of spinal tuberculosis (STB) in China remains substantial, with the country ranking third in the number of tuberculosis cases globally in 2022, among the 30 countries with a high tuberculosis burden. In East China, few large-scale studies have been conducted on STB.
Methods: This retrospective study analyzed 893 confirmed STB cases (2010-2020).